Humacyte, Inc. (HUMA)

US — Healthcare Sector
Peers: TRDA  ARCT  ACHV  VYGR  SGMT  IMRX  VNDA  FHTX  AVIR  NAUT 

Automate Your Wheel Strategy on HUMA

With Tiblio's Option Bot, you can configure your own wheel strategy including HUMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
HUMA
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system – – Symvess, the acellular tissue engineered vessel, is manufactured in this patented system – DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the issuance of a U.S. Patent covering key aspects of the manufacturing of Symvess (acellular tissue engineered vessel-tyod) and other bioengineered human tissues.

Read More
image for news Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
HUMA
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

– The FDA has authorized Humacyte to release commercial shipments – – Positive responses from surgeons and trauma centers to initial sales and marketing outreach – - 21 hospitals have already initiated the Value Analysis Committee (VAC) approval process – DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and …

Read More
image for news Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA
HUMA
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral

PHILADELPHIA, PA / ACCESS Newswire / February 20, 2025 / Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. ("Humacyte") (NASDAQ:HUMA) breached their fiduciary duties by failing to manage Humacyte in an acceptable manner and whether Humacyte and its shareholders were harmed as a result.

Read More
image for news Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

About Humacyte, Inc. (HUMA)

  • IPO Date 2020-12-01
  • Website https://www.humacyte.com
  • Industry Biotechnology
  • CEO Laura E. Niklason
  • Employees 218
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.